TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and efficacy of a new formulation of
an existing drug product called TAVT-45 in patients with metastatic prostate cancer.